Polycystic ovarian syndrome (PCOS) disrupts ovulation leading to both infertility and miscarriage; yet, its impact on obstetrical outcomes remains largely uncertain due to conflicting findings. We analyzed data from the CDC Pregnancy Risk Assessment of Monitoring System, specifically Standard Core and Phase 8 responses, with 9549 respondents across the United States through SPSS 28 software in this cross-sectional study. Two variables assessed PCOS status in respondents: history of PCOS and PCOS during pregnancy. With a history of PCOS, there were significantly increased odds of diabetic (OR 1.665, p < 0.001), hypertensive disorders (OR 1.589, p < 0.001) during pregnancy, neonatal mortality (OR 1.550, p < 0.001), cesarean section (C/S) (OR 1.489, p < 0.001), and preterm prelabor rupture of membranes (PPROM) (OR 2.081, p < 0.001). With PCOS diagnosed during pregnancy, there were significantly greater odds of diabetes (OR 3.278, p < 0.001), hypertensive disorders (OR 2.935, p < 0.001) during pregnancy, and significantly decreased risk for small for gestational age (2 standard deviations) (OR 0.337, p = 0.024). PCOS is a significant risk factor that contributes to maternal morbidity. Our results support the hypothesis that PCOS’ impact extends well into a woman’s obstetrical journey, with varying degrees of associated adverse maternal and fetal risks. Preliminary pathophysiologic explanations associated with PCOS gestational diabetes include pre-existing insulin resistance. Meanwhile, altered placentation and endovascular changes associated with PCOS secondary to a baseline deranged metabolic environment predispose patients to developing hypertensive disorders, PPROM, and preterm delivery. Associations between neonatal mortality and C/S can be attributed to elevated maternal body mass index. The pathophysiologic link between PCOS and the above obstetrical outcomes still remains unknown, necessitating further investigation; however, this study identifies the outcomes that require the most attention at this time.
References
[1]
Chiaffarino, F., Cipriani, S., Dalmartello, M., Ricci, E., Esposito, G., Fedele, F., et al. (2022) Prevalence of Polycystic Ovary Syndrome in European Countries and USA: A Systematic Review and Meta-Analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology, 279, 159-170. https://doi.org/10.1016/j.ejogrb.2022.10.020
[2]
Pundir, C., Deswal, R., Narwal, V. and Dang, A. (2020) The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. Journal of Human Reproductive Sciences, 13, 261-271. https://doi.org/10.4103/jhrs.jhrs_95_18
[3]
McCartney, C.R. and Marshall, J.C. (2016) Polycystic Ovary Syndrome. New England Journal of Medicine, 375, 54-64. https://doi.org/10.1056/nejmcp1514916
[4]
Giménez-Peralta, I., Lilue, M., Mendoza, N., Tesarik, J. and Mazheika, M. (2022) Application of a New Ultrasound Criterion for the Diagnosis of Polycystic Ovary Syndrome. Frontiers in Endocrinology, 13, Article 915245. https://doi.org/10.3389/fendo.2022.915245
[5]
Subramanian, A., Lee, S.I., Phillips, K., Toulis, K.A., Kempegowda, P., O’Reilly, M.W., et al. (2022) Polycystic Ovary Syndrome and Risk of Adverse Obstetric Outcomes: A Retrospective Population-Based Matched Cohort Study in England. BMC Medicine, 20, Article No. 298. https://doi.org/10.1186/s12916-022-02473-3
[6]
Mustaniemi, S., Vääräsmäki, M., Eriksson, J.G., Gissler, M., Laivuori, H., Ijäs, H., et al. (2018) Polycystic Ovary Syndrome and Risk Factors for Gestational Diabetes. Endocrine Connections, 7, 859-869. https://doi.org/10.1530/ec-18-0076
[7]
Cluver, C.A., Bergman, L., Bergkvist, J., Imberg, H., Geerts, L., Hall, D.R., et al. (2023) Impact of Fetal Growth Restriction on Pregnancy Outcome in Women Undergoing Expectant Management for Preterm Pre-Eclampsia. Ultrasound in Obstetrics & Gynecology, 62, 660-667. https://doi.org/10.1002/uog.26282
[8]
Qiu, Y., Zhang, X. and Ni, Y. (2022) Association between Polycystic Ovarian Syndrome and Risk of Gestational Diabetes Mellitus: A Meta-Analysis. Gynecologic and Obstetric Investigation, 87, 150-158. https://doi.org/10.1159/000521728
[9]
Fougner, S.L., Vanky, E., Løvvik, T.S. and Carlsen, S.M. (2021) No Impact of Gestational Diabetes Mellitus on Pregnancy Complications in Women with PCOS, Regardless of GDM Criteria Used. PLOS ONE, 16, e0254895. https://doi.org/10.1371/journal.pone.0254895
[10]
Peeva, M., Badeghiesh, A., Baghlaf, H. and Dahan, M.H. (2023) Adverse Obstetric Outcomes in Women with PCOS and Multiple Gestations. Reproductive BioMedicine Online, 46, 379-389. https://doi.org/10.1016/j.rbmo.2022.10.009
[11]
Wan, H.L.T., Hui, P.W., Li, H.W.R. and Ng, E.H.Y. (2014) Obstetric Outcomes in Women with Polycystic Ovary Syndrome and Isolated Polycystic Ovaries Undergoing inVitro Fertilization: A Retrospective Cohort Analysis. The Journal of Maternal-Fetal & Neonatal Medicine, 28, 475-478. https://doi.org/10.3109/14767058.2014.921673
[12]
Valgeirsdottir, H., Sundström Poromaa, I., Kunovac Kallak, T., Vanky, E., Akhter, T., Roos, N., et al. (2021) Polycystic Ovary Syndrome and Extremely Preterm Birth: A Nationwide Register-Based Study. PLOS ONE, 16, e0246743. https://doi.org/10.1371/journal.pone.0246743
[13]
Pan, M., Chen, L. and Chen, K. (2022) Prepregnancy Polycystic Ovary Syndrome as a Risk Factor of Subsequent Preterm Labor: A National Population-Based Cohort Study. International Journal of Environmental Research and Public Health, 19, Article 5470. https://doi.org/10.3390/ijerph19095470
[14]
Liu, M., Gao, J., Zhang, Y., Li, P., Wang, H., Ren, X., et al. (2015) Serum Levels of TSP-1, NF-κB and TGF-β1 in Polycystic Ovarian Syndrome (PCOS) Patients in Northern China Suggest PCOS Is Associated with Chronic Inflammation. Clinical Endocrinology, 83, 913-922. https://doi.org/10.1111/cen.12951
[15]
Abdelsalam, W.A., Harb, O.A. and Shazly, S.A. (2022) Antimullerian Hormone Levels and Association with Abortion and Preterm Delivery in Patients with Polycystic Ovary Syndrome Who Conceived with Assisted Reproductive Techniques. The Journal of Obstetrics and Gynecology of India, 72, 295-298. https://doi.org/10.1007/s13224-021-01506-w
[16]
Kaing, A., Jaswa, E.A., Diamond, M.P., Legro, R.S., Cedars, M.I. and Huddleston, H.G. (2021) Highly Elevated Level of Antimüllerian Hormone Associated with Preterm Delivery in Polycystic Ovary Syndrome Patients Who Underwent Ovulation Induction. Fertility and Sterility, 115, 438-446. https://doi.org/10.1016/j.fertnstert.2020.06.015
[17]
Qiu, M., Qu, J., Tian, Y. and Wang, Y. (2022) The Influence of Polycystic Ovarian Syndrome on Obstetric and Neonatal Outcomes after Frozen-Thawed Embryo Transfer. Reproductive BioMedicine Online, 45, 745-753. https://doi.org/10.1016/j.rbmo.2022.05.024
[18]
Mills, G., Badeghiesh, A., Suarthana, E., Baghlaf, H. and Dahan, M.H. (2020) Associations between Polycystic Ovary Syndrome and Adverse Obstetric and Neonatal Outcomes: A Population Study of 9.1 Million Births. Human Reproduction, 35, 1914-1921. https://doi.org/10.1093/humrep/deaa144
[19]
Bahri Khomami, M., Joham, A.E., Boyle, J.A., Piltonen, T., Silagy, M., Arora, C., et al. (2019) Increased Maternal Pregnancy Complications in Polycystic Ovary Syndrome Appear to Be Independent of Obesity—A Systematic Review, Meta-Analysis, and Meta-Regression. Obesity Reviews, 20, 659-674. https://doi.org/10.1111/obr.12829
[20]
Joham, A., Palomba, S. and Hart, R. (2016) Polycystic Ovary Syndrome, Obesity, and Pregnancy. Seminars in Reproductive Medicine, 34, 93-101. https://doi.org/10.1055/s-0035-1571195
[21]
Rogers, A.J.G., Harper, L.M. and Mari, G. (2018) A Conceptual Framework for the Impact of Obesity on Risk of Cesarean Delivery. American Journal of Obstetrics and Gynecology, 219, 356-363. https://doi.org/10.1016/j.ajog.2018.06.006
[22]
Yu, H., Chen, H., Rao, D. and Gong, J. (2016) Association between Polycystic Ovary Syndrome and the Risk of Pregnancy Complications: A PRISMA-Compliant Systematic review and meta-Analysis. Medicine, 95, e4863. https://doi.org/10.1097/md.0000000000004863
[23]
Boomsma, C.M., Eijkemans, M.J.C., Hughes, E.G., Visser, G.H.A., Fauser, B.C.J.M. and Macklon, N.S. (2006) A Meta-Analysis of Pregnancy Outcomes in Women with Polycystic Ovary Syndrome. Human Reproduction Update, 12, 673-683. https://doi.org/10.1093/humupd/dml036
[24]
Mann, A., Sagili, H. and Subbaiah, M. (2020) Pregnancy Outcome in Women with Polycystic Ovary Syndrome. The Journal of Obstetrics and Gynecology of India, 70, 360-365. https://doi.org/10.1007/s13224-020-01356-y
[25]
Chen, X., Gissler, M. and Lavebratt, C. (2022) Association of Maternal Polycystic Ovary Syndrome and Diabetes with Preterm Birth and Offspring Birth Size: A Population-Based Cohort Study. Human Reproduction, 37, 1311-1323. https://doi.org/10.1093/humrep/deac050
[26]
Doherty, D.A., Newnham, J.P., Bower, C. and Hart, R. (2015) Implications of Polycystic Ovary Syndrome for Pregnancy and for the Health of Offspring. Obstetrics & Gynecology, 125, 1397-1406. https://doi.org/10.1097/aog.0000000000000852
[27]
Shulman, H.B., D’Angelo, D.V., Harrison, L., Smith, R.A. and Warner, L. (2018) The Pregnancy Risk Assessment Monitoring System (PRAMS): Overview of Design and Methodology. American Journal of Public Health, 108, 1305-1313. https://doi.org/10.2105/ajph.2018.304563
[28]
Iavazzo, C. and Vitoratos, N. (2010) Polycystic Ovarian Syndrome and Pregnancy Outcome. Archives of Gynecology and Obstetrics, 282, 235-239. https://doi.org/10.1007/s00404-010-1495-0
[29]
Ashrafi, M., Sheikhan, F., Arabipoor, A., Hosseini, R., Nourbakhsh, F. and Zolfaghari, Z. (2014) Gestational Diabetes Mellitus Risk Factors in Women with Polycystic Ovary Syndrome (PCOS). European Journal of Obstetrics & Gynecology and Reproductive Biology, 181, 195-199. https://doi.org/10.1016/j.ejogrb.2014.07.043
[30]
Holte, J., Gennarelli, G., Wide, L., Lithell, H. and Berne, C. (1998) High Prevalence of Polycystic Ovaries and Associated Clinical, Endocrine, and Metabolic Features in Women with Previous Gestational Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism, 83, 1143-1150. https://doi.org/10.1210/jcem.83.4.4707
[31]
Hu, S., Xu, B., Long, R. and Jin, L. (2021) The Effect of Polycystic Ovary Syndrome without Hyperandrogenism on Pregnancy-Related Outcomes: A Retrospective Cohort Study. BJOG: An International Journal of Obstetrics & Gynaecology, 128, 1003-1010. https://doi.org/10.1111/1471-0528.16557
[32]
Roos, N., Kieler, H., Sahlin, L., Ekman-Ordeberg, G., Falconer, H. and Stephansson, O. (2011) Risk of Adverse Pregnancy Outcomes in Women with Polycystic Ovary Syndrome: Population Based Cohort Study. BMJ, 343, d6309-d6309. https://doi.org/10.1136/bmj.d6309
[33]
Pan, H., Xian, P., Yang, D., Zhang, C., Tang, H., He, X., et al. (2021) Polycystic Ovary Syndrome Is an Independent Risk Factor for Hypertensive Disorders of Pregnancy: A Systematic Review, Meta-Analysis, and Meta-Regression. Endocrine, 74, 518-529. https://doi.org/10.1007/s12020-021-02886-9
[34]
Anderson, H., Fogel, N., Grebe, S.K., Singh, R.J., Taylor, R.L. and Dunaif, A. (2010) Infants of Women with Polycystic Ovary Syndrome Have Lower Cord Blood Androstenedione and Estradiol Levels. The Journal of Clinical Endocrinology & Metabolism, 95, 2180-2186. https://doi.org/10.1210/jc.2009-2651
[35]
Kristensen, J., Vestergaard, M., Wisborg, K., Kesmodel, U. and Secher, N.J. (2005) Pre-Pregnancy Weight and the Risk of Stillbirth and Neonatal Death. BJOG: An International Journal of Obstetrics & Gynaecology, 112, 403-408. https://doi.org/10.1111/j.1471-0528.2005.00437.x
